Nvidia to Acquire Groq in $20 Billion Deal to Boost AI Chip Dominance 
Mexico Antitrust Review of Viva Aerobus–Volaris Deal Signals Growth for Airline Sector 
Sanofi to Acquire Dynavax in $2.2 Billion Deal to Strengthen Vaccines Portfolio 
TSMC Honors Japanese Chip Equipment Makers With 2025 Supplier Awards 
Hanwha Signals Readiness to Build Nuclear-Powered Submarines at Philly Shipyard for U.S. Navy 
Hyundai Recalls Over 51,000 Vehicles in the U.S. Due to Fire Risk From Trailer Wiring Issue 
BlackRock-Backed Global Ports Deal Faces Uncertainty Amid Cosco Demands 
Saks Global Weighs Chapter 11 Bankruptcy Amid Debt Pressures and Luxury Retail Slowdown 
Sanofi to Acquire Dynavax in $2.2 Billion Deal to Strengthen Vaccine Portfolio 
DOJ Reaches Settlement With Blackstone’s LivCor Over Alleged Rent Price-Fixing 
Nvidia and Groq Strike Strategic AI Inference Licensing Deal 
Eli Lilly and Novo Nordisk Battle for India’s Fast-Growing Obesity Drug Market 
BP Nears $10 Billion Castrol Stake Sale to Stonepeak 
California DMV Proposes New Safety Rules for Autonomous Vehicles After Waymo Incidents 
Winter Storm Devin Triggers Massive Flight Cancellations and Travel Disruptions Across the U.S. 
FTC Praises Instacart for Ending AI Pricing Tests After $60M Settlement 
ByteDance Plans Massive AI Investment in 2026 to Close Gap With U.S. Tech Giants 
BRIDGEWATER, N.J., Feb. 10, 2017 -- Valeritas Holdings, Inc. (OTCQB:VLRX) announced today that the Company will release its fourth quarter and full year 2016 financial results on Tuesday, February 21, 2017 before the market opens.
Valeritas will hold a conference call on Tuesday, February 21, 2017 at 10:00 a.m. EST / 7:00 a.m. PST to discuss the results. The dial-in numbers are (877) 201-0168 for domestic callers and (647) 788-4901 for international callers. The conference ID number is 65023780. A live webcast of the conference call will be available on the investor relations page of the Valeritas corporate website at www.valeritas.com.
After the live webcast, a replay of the webcast will remain available online until the Company reports second quarter 2017 financial results on the investor relations page of the Valeritas corporate website, www.valeritas.com. In addition, a telephonic replay of the call will be available through February 22, 2017. The replay dial-in numbers are (800) 585-8367 for domestic callers and (416) 621-4642 for international callers. Please use the replay pin number 65023780.
About Valeritas, Inc.
Valeritas is a commercial-stage medical technology company focused on improving health and simplifying life for people with diabetes by developing and commercializing innovative technologies. Valeritas’ flagship product, V-Go® Wearable Insulin Delivery device, is a simple, wearable, basal-bolus insulin delivery solution for patients with Type 2 diabetes that enables patients to administer a continuous preset basal rate of insulin over 24 hours. It also provides on-demand bolus dosing at mealtimes. It is the only basal-bolus insulin delivery device on the market today specifically designed keeping in mind the needs of type 2 diabetes patients. Headquartered in Bridgewater, New Jersey, Valeritas operates its R&D functions in a state-of-the-art facility in Shrewsbury, Massachusetts. For more information, please visit www.valeritas.com.
Investor Contacts: Nick Laudico / Robert Flamm, Ph.D. The Ruth Group (646)536-7030 / 7017 [email protected] Or The Del Mar Consulting Group, Inc. Robert B. Prag, President 858-794-9500 [email protected] Media Contact: Kirsten Thomas The Ruth Group (508)280-6592 [email protected]
